43 results about "Maintenance therapy" patented technology

The present invention provides a method of effectively measuring risk for therapeutic toxicity of a subject having an autoimmune disorder or cancer and predicting and evaluating therapeutic efficacy of immunosuppressive therapies for autoimmune diseases and cancers before or after starting therapy. The present invention also provides for determining a drug metabolite level of a subject during therapy and measuring periodically the drug metabolite level of a subject on maintenance therapy to ensure treatment compliance and continued therapeutic response by measuring minimal clinical important differences (MCID) in the drug metabolite levels. The present invention also provides for a method to effectively optimize the selection and dose of immunosuppressive therapies of a subject having an autoimmune disease or cancer to improve therapeutic efficacy and reduce therapeutic toxicity prior to starting concomitant biologic therapy and before or after the subject has failed to respond to the at least one immunosuppressive agent.

A wearable maintenance therapy device (10, 12, 14) imparts vibratory stimuli to appendicular muscles of a patient's limb during daily life activity of the patient to reduce symptomatic relapse of spasticity. A vibrator actuator (20) contained in a sup port housing (24) and configured for placement in operational contact with appendicular muscles of a limb (28) of a patient imparts localized vibration to one or more of the patient's appendicular muscles. The localized vibration produces proprioceptive input from the vibrated muscle or muscles (90t) to activate sensory areas of the patient's central nervous system. Programmable electrical control circuitry (50) controls vibration characteristics of the localized vibration and includes memory sites for storing operating values of the vibration characteristics. The vibration characteristics include pattern and timing of vibration specified to produce the proprioceptive input during the patient's daily life activity to mitigate any symptomatic relapse of spasticity.

A system and method for assessing global wellness and developing a maintenance/treatment program are provided, wherein a plurality of data sources are compiled, including, at minimum (a) a subject's medical, dental and family histories, and (b) a body fluid sample (e.g. an oral swab or saliva) for detecting and determining levels of one or more biomarkers, and wherein these data are used to assess the subject's global health and wellness landscape, which is then compared to a reference/ideal wellness landscape, and the comparison used to design a maintenance therapy/treatment plan.

The present invention provides for a method of using adapalene for the maintenance theray of acne vulgaris to prevent acne recurrence or reduce the severity of the acne recurrence.

The present invention provides a method of administering adapalene for the maintenance therapy of acne vulgaris to prevent acne recurrence or reduce the severity of the acne recurrence.

The invention includes methods for treating tobacco addiction and nicotine addiction of patients, alleviating nicotine withdrawal symptoms, providing or promoting curative effect of smoking cessation treatment and as long-term smoking cessation maintenance treatment. The invention also relates to a pharmaceutical composition comprising a nicotine receptor antagonist and an antidepressant or an anxiolytic. A specific combination of drugs (mecamylamine hydrochloride and bupropion hydrochloride) and a pharmaceutical composition formed by combining mecamylamine with certain types of drugs (such as anxiolytics and antidepressants) are disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.

A novel maintenance therapy regime/regimen for the treatment of acne related diseases includes administering an oral antibiotic with a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide.

The present invention relates to the use of a composition comprising:

• • (a) formoterol, a pharmaceutically acceptable salt of formoterol, a solvate of formoterol, or a solvate of a pharmaceutically acceptable salt of formeterol; and
  • (b) beclometasone dipropionate;

for the prevention and/or treatment of an exacerbation of asthma, intermittent asthma and/or episodes in chronic asthma during the maintenance therapy of asthma with the same composition for symptomatic relief, when needed.

The invention relates to a tulobuterol transdermal patch and belongs to the field of transdermal medicinal preparation. According to the tulobuterol transdermal patch disclosed by the invention, tulobuterol is prepared into a drug reservoir; the tulobuterol transdermal patch is prepared from tulobuterol, a penetration enhancer, carbopol and polysiloxane pressure sensitive adhesive; specific matrixcombination and use amount are utilized to for controlling drug release speed, and finally, the purpose of stably releasing drugs for 24 hours is achieved. The tulobuterol transdermal patch is pastedand applied before sleeping, and the plasma concentration can reach peak concentration from late night to early morning when a respiratory function of a patient is prone to reduce; thus, the respiratory function can be improved, a cumulative effect is avoided when the tulobuterol transdermal patch is continuously used, and untoward effects of drugs are reduced. Furthermore, the tulobuterol transdermal patch disclosed by the invention is less affected by environment change, can be stably stored for a long time and can be applied to long-time maintenance therapy of bronchial asthma and chronicobstructive pulmonary disease patients.

The invention relates to a fast-effect slow-release sustained-release metoprolol dropping pill used for treating hypertension, angina, the maintenance therapy after myocardial infarction and hyperthyroidism and the preparation method thereof, and aims to supplement the deficiency of the prior art and provide a sustained-release metoprolol dropping pill. The sustained-release metoprolol dropping pill is added with a hydrophobic framework capable of sustaining drug release and tween-80 playing the role of solubilization on the basis of the existing dropping pill technology, thereby overcoming the defects in the prior art effectively and having the advantages of even drug distribution, full release, long release time, reduced frequency of drug taking for patients and high bioavailability simultaneously.

The invention discloses an isosorbide 5-mononitrate nasal drug delivery composition for treating coronary heart diseases and angina, and a preparing method thereof. The nasal drug delivery composition comprises isosorbide 5-mononitrat, a solvent and a preservative, and optionally comprises an absorption enhancer, an osmotic pressure regulator and other pharmaceutic adjuvants. The composition has simple preparing process and stable and controllable quality, and is suitable for industrial production. The preparation is quickly absorbed, takes effect in 3-5 minutes, achieves the maximum drug effect after 15 minutes, has high bioavailability, convenient use, and good compliance of patients, is especially suitable for delivering drugs to the middle and old patients, dysphagia patients and bedrid patients, is suitable for delivering drugs for patients with coronary heart diseases and angina in acute attach period at the first time, obtains valuable time for rescuing patient lives, and has significant clinical meaning on long-term continuous prevention and maintenance therapy.

Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.

The present disclosure relates to a maintenance therapy for prolongation of remission of a cancer comprising administering a therapeutically effective amount of a compound of formula (I) an enantiomer thereof or pharmaceutically acceptable salt of any one of the same or a pharmaceutical composition thereof.

The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating myelodysplastic syndrome in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.

The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating hepatocellular adenocarcinoma in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.

This invention provides a method of treating a subject afflicted with multiple sclerosis (MS) or presenting clinically isolated syndrome (CIS) which comprises a) administering to the subject an amount of an anti-CD52 antibody, followed by b) periodically administering to the subject an amount of laquinimod. This invention also provides packages comprising pharmaceutical compositions of laquinimod or an anti-CD52 antibody for treating such a subject wherein laquinimod is to be administered as a maintenance therapy in such a subject who has received an anti-CD52 antibody induction therapy.